Vyvgart Efgartigimod Alfa FcRn Blocker Myasthenia Gravis Review 2026
Author: Critical Kare PharmaSpecialty Biologics Desk
On October 28, 2026, neurological and immunological societies underscored Vyvgart® (Efgartigimod alfa-fcab 400 mg/20 mL vial) and Vyvgart Hytrulo® by argenx as groundbreaking treatments for generalized Myasthenia Gravis (gMG).
As the first FDA/EMA-approved neonatal Fc receptor (FcRn) blocker, efgartigimod engineered human IgG1 antibody Fc fragments competitively bind FcRn, accelerating pathogenic anti-AChR autoantibody degradation without non-specifically suppressing cellular immunity.
Through Critical Kare Pharma, verified original manufacturer packs of Vyvgart Efgartigimod Solution for Infusion are delivered under validated 2°C–8°C cold-chain logistics to clinics globally.
Mechanism of Action & ADAPT Clinical Evidence
- Selective IgG Depletion: Reduces circulating total IgG and pathogenic anti-acetylcholine receptor autoantibodies by >60% while sparing IgM, IgA, and albumin.
- ADAPT Trial Success: 68% of AChR-Ab+ patients demonstrated significant, clinically meaningful MG-ADL score improvements sustained through cyclical dosing.
- Dosing: 10 mg/kg administered as an IV infusion over 1 hour once weekly for 4 weeks (one cycle), with subsequent cycles guided by clinical evaluation.
Global Named-Patient Sourcing
Sourced legally under US FDA PIP, UK Named-Patient Import, and Latin American health permits with end-to-end digital temperature monitoring.
